Non-urothelial cancers account for around 10% of cancers of the urinary tract. Learn about the different subtypes and how best to manage them in this comprehensive review.
Several retrospective and prospective studies have evaluated the outcomes of planned discontinuation of tyrosine kinase inhibitors in patients with renal cell carcinoma, and the strategy appears to be viable.
Radiation plays a large and continually evolving role in the management of high-risk prostate cancer, yet outcomes are still suboptimal. There is a growing need to improve upon current treatment approaches, and better personalize treatment.
Among the many tools for characterizing individual tumors, immunohistochemistry and DNA sequencing have thus far proved most useful to guide treatment in people with urothelial cancer. Currently available markers and future directions are discussed.
An overview of the signaling pathways involved in the progression of renal cell carcinoma, key biomarkers, and current management and future therapeutic options.
Combined treatment with enfortumab vedotin plus pembrolizumab has achieved an overall survival benefit in previously untreated advanced urothelial cancer.
Adjuvant pembrolizumab treatment after resection of lung metastases in a patient with renal cell carcinoma may have led to lung erosion that resulted in a pneumothorax.
Patients with oligometastatic castration-resistant prostate cancer benefit from the addition of stereotactic body radiotherapy to first-line abiraterone acetate plus prednisone.
The key clinical trial results for agents targeting the PI3K/AKT/mTOR signaling pathway in cancer are outlined and the major mechanisms of resistance to these inhibitors are discussed.
Emerging genomic and phenotypic biomarkers, combined with medical imaging technologies, aim to improve clinical risk stratification and precision medicine in advanced prostate cancer.
Results from ongoing clinical trials with HIF-2α inhibitors have been promising and may ultimately provide important treatment paradigm shifts for patients with metastatic renal cell carcinoma.
Adding talazoparib to enzalutamide significantly improves the outcomes of untreated patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair mutation status.
Avelumab shows promise as a second-line treatment option in a patient with collecting duct carcinoma of the kidney, but further studies assessing its use in this setting are needed.
Recent advancements in the design and delivery of DNA-based cancer vaccines, together with the identification of optimal tumor antigens, have shown great potential in preclinical and clinical studies.
Systematic investigation of anemia in a patient receiving immune checkpoint inhibitor treatment for metastatic castration-resistant prostate cancer revealed a diagnosis of secondary pure red cell aplasia with underlying Waldenström macroglobulinemia.
